MK-7684A is a fixed dose compound formulation composed of Merck Vibostolimab (MK-7684) and Pembrolizumab (K-drug), which can block the interaction between TIGIT/PD-1 and its ligand, thereby activating T lymphocytes and enhancing the attacking ability of tumor cells. The gene discussed is PDCD1; the disease is neoplasm.